Table 1.
Characteristics of atopic and non-atopic COPD patients in the EUROSCOP study stratified by gender
|
Baseline variables |
Males (843 patients) |
Females (320 patients) |
||||
|---|---|---|---|---|---|---|
| |
Atopic |
Non-atopic |
p. value |
Atopic |
Non-atopic |
p. value |
| n = 181 | n = 662 | n = 32 | n = 288 | |||
|
Age, yr |
53.0 (48.0–58.0) |
54.0 (48.0–59.0) |
0.164 |
51.0 (46.0–58.7) |
52.0 (47.0–58.0) |
0.391 |
|
Height, cm |
176 (172–181) |
176 (171–180) |
0.403 |
165.5 (160.5–169.7) |
165 (160–169) |
0.494 |
|
Weight, kg |
80.0 (72.0–88.0) |
78.0 (70.0–85.0) |
0.017 |
64.0 (58.5–73.7) |
62.0 (55.0–70.0) |
0.206 |
|
BMI, kg/m2 |
25.3 (23.5–27.5) |
24.8 (22.6–27.1) |
0.016 |
23.8 (21.8–25.9) |
22.9 (21.0–25.4) |
0.205 |
| Underweight (<18.5) |
2 (1.1%) |
7 (1.1%) |
|
0 (0.0%) |
17 (5.9%) |
|
| Normal weight (18.5–24.9) |
77 (42.5%) |
342 (51.7%) |
0.102# |
20 (62.5%) |
186 (64.6%) |
0.277# |
| Overweight/Obese (≥25) |
101 (55.8%) |
312 (47.1%) |
|
12 (37.5%) |
84 (29.2%) |
|
|
Packyears of smoking |
40.0 (29.2–55.5) |
38.7 (28.5–50.0) |
0.288 |
32.5 (26.7–36.0) |
29.9 (21.3–39.0) |
0.462 |
|
FEV1, liter* |
2.7 (2.4–3.3) |
2.8 (2.3–3.2) |
0.680 |
2.1 (1.6–2.4) |
2.0 (1.7–2.4) |
0.904 |
|
FEV1 % pred.* |
78.7 (69.4–87.0) |
79.3 (68.1–89.1) |
0.685 |
79.4 (63.6–89.2) |
80.8 (70.5–88.5) |
0.666 |
|
FEV1%FVC* |
63.9 (56.7–68.5) |
64.4 (58.1–68.7) |
0.443 |
66.4 (61.4–70.0) |
65.5 (60.9–70.4) |
0.823 |
|
Reversibility % pred. |
2.9 (0.8–5.2) |
2.8 (0.0–5.4) |
0.932 |
3.2 (0.3–7.6) |
2.9 (0.0–5.5) |
0.323 |
| Total IgE, kU/l** | 248.5 (84.0–617.2) | 37.0 (15.0–82.0) | <0.0001 | 161.0 (25.5–1373.0) | 28.0 (13.0–75.0) | 0.002 |
Data are presented as median (interquartile range) or number (%). Bold p-values lower than 0.05 indicate significant differences between atopic and non-atopic patients within males or females.
*Respiratory function tests were performed after inhalation of 1 mg terbutaline.
**Available in 678 patients.
#P.value refers to Chi-square analysis between classes of BMI and atopy.